As of 2026-09-25, the EV/EBITDA ratio of Summit Therapeutics Inc (SMMT) is -21.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SMMT's latest enterprise value is 12,647.78 mil USD. SMMT's TTM EBITDA according to its financial statements is -575.12 mil USD. Dividing these 2 quantities gives us the above SMMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-09-24 | -21.99 |
| 2026-09-23 | -22.09 |
| 2026-09-22 | -23.02 |
| 2026-09-21 | -22.71 |
| 2026-09-18 | -24.03 |
| 2026-09-17 | -23.85 |
| 2026-09-16 | -23.27 |
| 2026-09-15 | -23.41 |
| 2026-09-14 | -24.82 |
| 2026-09-11 | -23.61 |
| 2026-09-10 | -22.85 |
| 2026-09-09 | -23.60 |
| 2026-09-08 | -23.24 |
| 2026-09-04 | -23.69 |
| 2026-09-03 | -23.03 |
| 2026-09-02 | -19.52 |
| 2026-09-01 | -18.91 |
| 2026-08-31 | -18.16 |
| 2026-08-28 | -18.32 |
| 2026-08-27 | -19.15 |
| 2026-08-26 | -19.01 |
| 2026-08-25 | -17.80 |
| 2026-08-24 | -16.93 |
| 2026-08-21 | -17.53 |
| 2026-08-20 | -16.51 |
| 2026-08-19 | -17.46 |
| 2026-08-18 | -17.05 |
| 2026-08-17 | -17.00 |
| 2026-08-14 | -17.79 |
| 2026-08-13 | -18.69 |
| 2026-08-12 | -20.22 |
| 2026-08-11 | -20.24 |
| 2026-08-10 | -19.90 |
| 2026-08-07 | -18.63 |
| 2026-08-06 | -18.05 |
| 2026-08-05 | -18.04 |
| 2026-08-04 | -18.36 |
| 2026-08-03 | -17.37 |
| 2026-07-31 | -17.33 |
| 2026-07-30 | -17.91 |
| 2026-07-29 | -17.03 |
| 2026-07-28 | -16.68 |
| 2026-07-27 | -17.45 |
| 2026-07-24 | -18.22 |
| 2026-07-23 | -20.05 |
| 2026-07-22 | -19.72 |
| 2026-07-21 | -19.56 |
| 2026-07-20 | -18.00 |
| 2026-07-17 | -18.43 |
| 2026-07-16 | -18.36 |